Increased Axl levels have been linked to resistance to Imatinib in gastrointestinal stromal tumors, Lapatinib in HER-2 positive breast tumor cells53, BMS-754087 in Rhabdomyosarcoma54, and metformin in PCa55, as well as erlotinib in non-small cell lung cancer (NSCLC)32. Here, AXL is linked to breast neoplasm.